Alvotech reports record revenues and adjusted ebitda for the second quarter and first six months of 2024

Reykjavik, iceland, aug. 15, 2024 (globe newswire) -- alvotech (nasdaq: alvo, or the “company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2024 and provided a summary of recent corporate highlights.

ALVO Ratings Summary

ALVO Quant Ranking